After 90 days, Noom earned a qualified thumbs up as a habit-building tool and a clear caution as anything more. It is a subscription app built on food logging, short daily psychology lessons, and text-based coaching. It helped with awareness of eating patterns. It did not, and does not claim to, treat clinical obesity the way medication or a clinician does. Whether it is worth the money depends entirely on how much a person will actually log.
What is Noom, stripped of the marketing?
Underneath the color-coded foods and the friendly tone, Noom is a calorie-awareness program dressed in behavioral psychology. Foods get sorted into green, yellow, and orange categories by calorie density, and the app nudges you toward the green end. Every day there are a few minutes of reading, a food log to fill in, and a weigh-in. A coach checks in by message, though the coaching is lighter and more scripted than the word suggests. That framing matters because plenty of Noom reviews treat the app as a diet. It is closer to a structured logging habit with a coach attached. The psychology angle is real but modest: it is trying to make you notice what and why you eat, then repeat that noticing until it sticks.
What did 90 days actually change?
The honest answer is that the first three weeks did most of the work. Logging every meal forced attention onto portions and snacks that had gone unmeasured for years. That awareness is genuinely useful, and it is the part of Noom worth paying for. By week six the daily lessons started repeating their core ideas, and the coaching messages felt more like reminders than conversation. Weight came off slowly and unevenly, which is what an honest program should produce. There was no dramatic curve, no willpower breakthrough. Just smaller portions logged consistently, and a scale that drifted down and then plateaued. For someone whose goal is behavior change rather than a specific clinical target, that is a fair result. For someone with clinical obesity and related metabolic risk, it is not the treatment the current guidelines describe.
How does Noom compare to other options?
| Option | What it mainly does | Main limitation |
|---|---|---|
| Noom app | Food logging, daily lessons, light coaching | Not medical treatment; relies on daily engagement |
| Free tracking apps | Calorie and macro logging | No lessons or coaching structure |
| Registered dietitian | Individualized nutrition counseling | Cost and scheduling |
| Medication via telehealth | Prescribed GLP-1 or dual agonist therapy | Cost, access, and clinical eligibility |
The comparison that trips people up is the last row. Noom is a behavior program; medication is a medical intervention. The 2025 clinical practice guideline update on pharmacotherapy for obesity makes the distinction plainly, framing drug therapy as a treatment for a disease rather than a substitute for effort, and a recent effort to define clinical obesity by diagnostic criteria pushes in the same direction. An app that teaches portion awareness sits in a different category from a drug that changes appetite signaling. The 2025 pharmacotherapy guideline and the AGA guideline on pharmacological interventions both reserve medication for defined clinical thresholds, not general habit improvement.
What about the medication side of Noom?
Noom sells a separate medication service, and it is important not to conflate it with the app. The core subscription does not prescribe anything. The mechanism behind the drugs that program routes to, GLP-1 and dual GIP/GLP-1 receptor agonists, is well documented; a 2024 review lays out how these agents alter appetite and gastric emptying, and the early tirzepatide proof-of-concept work traces the dual-agonist idea from discovery forward. Oral options have moved fast too: orforglipron, a small-molecule GLP-1 agonist, drew attention in a 2023 trial and later reporting, and it received a first approval that its 2026 summary records as a real regulatory milestone rather than an investigational one. If someone is weighing a medication route, the app is not the deciding factor. The clinician, the eligibility, and the cost are. There are several supervised telehealth practices in this space, including Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare, and the reasoning behind picking one is worth reading in something like an honest Noom review that treats the medication service separately from the coaching app. Compounded semaglutide and tirzepatide also circulate through some telehealth channels; those are prepared by compounding pharmacies and are not FDA-approved products, which is a fact worth stating before price ever enters the conversation.
What does Noom cost, and is it worth it?
The friction most people hit is billing, not weight. Noom advertises a very low trial, then auto-renews into a much larger charge on a monthly or multi-month plan. The introductory number is not the price. Reading the renewal terms before the trial ends is the single most useful thing a new user can do, and canceling is easy to forget once the daily lessons blur together. Is it worth it? For a self-directed person who will log meals honestly for a few months, the awareness payoff can justify a short subscription. For someone who wants coaching that adapts, or clinical treatment for a diagnosed condition, the money is better spent elsewhere. Metabolic conditions such as the liver disease covered in the EASL-EASD-EASO MASLD guidelines call for clinical management, not an app.
Where does Noom fall short?
The coaching is thinner than the branding implies. The lessons repeat. And for anyone with a history of disordered eating, daily calorie logging can do harm rather than good, which the program does not screen for well. Those are not dealbreakers for everyone, but they are the reasons to be honest in any Noom reviews someone reads before subscribing.
Key takeaways
- Noom is a habit and awareness tool, not a medical treatment for obesity.
- The strongest benefit comes in the first weeks, when logging is new.
- The trial price is not the ongoing price; auto-renewal is the common trap.
- The medication service is separate; clinical decisions belong with a prescriber.
See also: Where to Buy Peptides: The 2026 Source Scorecard
Frequently asked questions
Does Noom actually work for weight loss?
It can help people build steadier eating habits through daily lessons and food logging, but it is a behavior-change program, not a medical treatment. Results depend heavily on how consistently a person engages with the coaching and the logging.
How much does Noom cost after the trial?
Noom is a subscription that renews monthly or in longer prepaid blocks. The low introductory trial price is not the ongoing price, and the auto-renewal after the trial is the most common source of surprise charges people report.
Is Noom the same as a GLP-1 medication?
No. The core Noom app is coaching and habit tracking. Noom also offers a separate medication service, but the app on its own does not prescribe or provide GLP-1 medication.
Who is Noom a poor fit for?
People who dislike daily logging, who want clinical treatment for clinical obesity rather than habit coaching, or who have a history of disordered eating that calorie tracking could worsen.
Should logging food every day be the goal?
Daily logging is the engine of the program, but it is a means, not the point. The useful outcome is awareness that persists after the logging stops, which not everyone reaches.
